
AstraZeneca COVID-19 vaccine shows 76% efficacy against symptomatic infection in updated data
Fox News
AstraZeneca on Thursday published an updated analysis confirming that a Phase 3 trial involving its COVID-19 vaccine was safe and effective, and showed to be 76% effective against symptomatic COVID-19.
The earlier data reflected 79% efficacy in preventing symptomatic infections and 100% efficacy at preventing severe disease and hospitalization. The new analysis also reported 100% efficacy "against severe or critical disease and hospitalization." "Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the U.S. have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021," a press release posted by AstraZeneca early Thursday stated. "These results have been presented to the independent Data Safety Monitoring Board. The primary analysis is pre-specificed in the protocol and will be the basis for a regulatory submission for Emergency Use Authorization to the U.S. Food and Drug Administration in the coming weeks."More Related News

Pizza before tomatoes? Ancient Rome's version of America's favorite food looked nothing like today's
Ancient Rome pizza at Hungary restaurant features no tomatoes or mozzarella, using garum fish sauce and olive paste. Neverland Pizzeria's dish is limited-edition.












